Cells for Sight News Publication
- New research programme into Aniridia to go ahead at Moorfields Eye Hospital
- CFS will give five paper presentations and two posters at ARVO
- Hannah Levis awarded ARVO International Travel Grant
- UCLB patented technology used to develop a potential new treatment for Corneal Surface Disease
- Stefan Schrader successfully defends his PhD thesis
- Cells for Sight to host 5th Limbal Stem Cell Conference at UCL
- Hannah Levis appears in ESCRS Eurotimes
- Prof Julie Daniels invited speaker at the Gordon Conference in California
- Hannah Levis presents at the BCLA Evening Meeting
- New Postdoc joins the group
- Congrats to Marc for running the Paris Marathon!
- Julie Daniels interview on Insight Radio
- Eye disease cash for TAP Biosystems
- TAP, UCL Receive Additional Funding to Take Biomimetic Cornea into Human Safety Study
- New Scientific Data on use of Stem Cells for Ocular Surface Regeneration Presented by Daniels’ Group at Prestigious Ophthalmology Conference, ARVO
- ARVO 2012 report
- International Conference on Stem Cells and Regenerative Medicine
- Julie Daniels Fellow of the Society of Biology
- Welcome to Nuria Genicio!
- London 2012 Olympics is here!
- Farewell Marina!
- Welcome Sara Galindo!
- New research technician joins CFS
- 5th Limbal Stem Cell Meeting
- Recent Publications from CFS
- Alvena visits Prof. Funderburgh's lab in Pittsburgh
- Sarah and Alvena present at London Matrix Group
- Levis et al. manuscript accepted for publication in PLOS ONE
- Amanda Vernon successfully upgrades from MPhil to PhD
- We welcome a new member of CfS- Louise Morgan
- CfS do Movember!
- CfS Christmas Lunch
- New Endothelial RAFT article published in PLOS ONE available online now
- Aniridia Europe Meeting, Italy 2012
- CfS awarded UCL Beacon Bursary to host public engagement event
- Marc Dziasko successfully upgrades from MPhil to PhD
- Hannah and Victoria attend Aniridia Network UK Conference
- Alvena and Isobel visit Istanbul to attend TERMIS
- Marc attends the ISSCR annual conference
- Julie, Louise, Alex and Steve visit Japan
- Hannah and Marc present at the Vision of Excellence Congress in Berlin
- Cells for Sight team attend the 6th Limbal Stem Cell Forum in Liverpool
- Hannah has her paper published in Biomaterials
- Alex has his paper published in Stem Cells Translational Medicine
- Cornea Connect 2014
- Marc Dziasko has his paper published in PLoS ONE
- Hannah and Victoria raise £115 for Aniridia Network UK
UCLB patented technology used to develop a potential new treatment for Corneal Surface Disease
25 April 2012
Researchers at UCL have made a significant advance towards developing a treatment for Corneal Surface Disease, using RAFTTM; a UCLB patented technology licensed to Tap Biosystems.
The development was led by Professor Robert Brown at UCL's Tissue Repair and Engineering Centre (TREC) and Professor Julie Daniels at the UCL's Institute of Ophthalmology, in collaboration with TAP Biosystems and funding from the Technology Strategy Board.
Professor Daniels used an innovative method of synthetic tissue production, known as RAFTTM, which uses collagen to create corneal tissue; closely mimicking that of actual human cornea. It has the potential to significantly improve the success rates of cornea repair surgery and will allow people with corneal surface disease to have replacements without waiting for eye donors.
The patented RAFTTM technology has previously been used to create a wide range of different artificial human tissues. This is the first time it has successfully been used to mimic that of human cornea tissue.
"This project has advanced our understanding of what is required to engineer a tissue in the laboratory for patient transplantation," explains Julie Daniels, Professor of Regenerative Medicine and Cellular Therapy at the Institute of Ophthalmology. "It's exciting because it provides a real prospect for treating patients with blinding corneal surface disease, using a stem cell populated tissue equivalent that is simply, quickly and reproducibly prepared."
Dr Rachel Hemsley, Senior
Business Manager at UCLB said "This project is an exciting contribution
of disciplines bringing together regenerative medicine and tissue
engineering with the aim of meeting a key medical need of restoring
sight to patients. This advance has arisen through the long standing
relationship between IoO at UCL, UCLB and Tap Biosystems".
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK's top research-led universities.
UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from the laboratory to market.
UCLB supports UCL's Grand Challenges of increasing UCL's positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit www.uclb.com
About Tap Biosytems
TAP Biosystems (formerly The Automation Partnership) provides advanced automation systems and services to improve productivity in life science research, development and production.
For further information, please visit www.tapbiosytems.com
Published 14 February 2012 on UCL Enterprise
Page last modified on 25 apr 12 13:55